Difference between revisions of "Alitretinoin (Panretin)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alitretinoin NCI Drug Dictionary]: An orally- and topically-active naturally...") |
m (→Also known as) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20886lbl.pdf Alitretinoin (Panretin) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20886lbl.pdf Alitretinoin (Panretin) Package Insert]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with [[Kaposi sarcoma|AIDS-related Kaposi’s sarcoma]]. ''(Based on Walmsley et al. 1999 & Bodsworth et al. 2001)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' ALRT-1057, LGD-1057 |
*'''Brand names:''' Panretin, Panretyn, Panrexin | *'''Brand names:''' Panretin, Panretyn, Panrexin | ||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Topical medications]] | [[Category:Topical medications]] | ||
Latest revision as of 02:06, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.
Diseases for which it is used
Patient Drug Information
History of changes in FDA indication
- 1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. (Based on Walmsley et al. 1999 & Bodsworth et al. 2001)
Also known as
- Code names: ALRT-1057, LGD-1057
- Brand names: Panretin, Panretyn, Panrexin